Final Thoughts While semaglutide has shown promise in weight loss and metabolic health improvements, its use for weight loss alone is controversial
Reference: Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial by John Deanfield, Subodh Verma, Benjamin M Scirica, Steven E Kahn, Scott S Emerson, Donna Ryan, Ildiko Lingvay, Helen M Colhoun, Jorge Plutzky, Mikhail N Kosiborod, G Kees Hovingh, Sren Hardt-Lindberg, Ofir Frenkel, Peter E Weeke, Sren Rasmussen, Assen Goudev, Chim C Lang, Miguel Urina-Triana, Mikko Pietil, A Michael Lincoff, Mitsunori Abe, Rajpal K Abhaichand, Walter P Abhayaratna, Atul Abhyankar, Imran B Zainal Abidin, Hiba Abou Assi, Jose L Accini Mendoza, Mine Adas, John M Agaiby, Devendra K Agarwal, Maher Agha, Azazuddin Ahmed, Petteri Ahtiainen, Elmar Aigner, Naik Ajay, Norsiah Ali, Amer Al-Karadsheh, Roy Allison, Dale C Allison, Diana Alpenidze, Yuksel Altuntas, Ayham Al-Zoebi, Roy Ambuj, John Amerena, Robert J Anderson, Toshiaki Ando, Robert Andrews, Elizaveta Antonova, Karl-Friedrich Appel, Flvia B Arantes, Mustafa Araz, Yaron Arbel, Jos L Arenas Len, Georgia Argyrakopoulou, Mehrdad Ariani, Maria A Arias Mendoza, Ahmed A Arif, Jaspal Arneja, Vanita R Aroda, Louis J Aronne, Margaret Arstall, Njaimeh Asamoah, Milika Asanin, Hanid Audish, Rodica Avram, Aysha Badat, Corin V Badiu, Wael Bakdash, Okan S Bakiner, Vuyokazi N Bandezi, Liew H Bang, Sandeep Bansal, Marietta Baranyai, Olga Barbarash, Mark Barber, Otis Barnum, Gilles Barone Rochette, Amir Bashkin, Seth Baum, Harold E Bays, Alberto E Bazzoni Ruiz, Maciej Beckowski, Yaswin Beerachee, Srikanth Bellary, Lidia Belousova, Martin Berk, Marc Bernstein, Cesare Berra, Isaac Beshay, Ajit Bhagwat, Arti Bhan, William C Biggs, Liana Billings, Fahed Bitar, Bradley Block, Simona Bo, Pawel Bogdanski, Olga O Bolshakova, Alla A Boshchenko, , Iwona Wozniak, Chau-Chung Wu, Nell Wyatt, Alan Wynne, Hiroshi Yamaguchi, Masahiro Yamasaki, Dilek Yazici, Hung-I Yeh, Yoto Yotov, Qingyang Yuan, Jeffrey Zacher, Olga Zagrebelnaya, Cesar J Zaidman, Alsu Zalevskaya, Stuart Zarich, Maria Chiara Zatelli, Helga Zeller, Elena A Zhdanova, Taiba Zornitzki, Konstantin Zrazhevskiy, Mikhail Zykov, A Michael Lincoff, Donna H Ryan, Helen M Colhoun, John E Deanfield, Scott S Emerson, Steven E Kahn, Robert F Kushner, Jorge Plutzky, Kirstine Brown-Frandsen, G Kees Hovingh, Soren Hardt-Lindberg and Christoffer W Torne, 24 August 2024, The Lancet
These side effects usually subside as the body adjusts to the higher vitamin levels
Coutinho-Wolino KS, de F Cardozo LFM, de Oliveira Leal V, Mafra D, Stockler-Pinto MB
In phase 3 trials, semaglutide and tirzepatide achieved between 14.9% and 20.9% reduction in body weight after one year, as well as improvement on cardiovascular risk factors (Jastreboff et al., 2022
